Does off-label dosing of NOACs increase the risk of adverse events in U.S. patients with atrial fibrillation?
U.S. patients in the community with atrial fibrillation (from the ORBIT-AF II registry)
Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) dosed inconsistently with labeling (over- and underdosing)
NOAC doses consistent with labeling
Adverse eventssafety
Off-label dosing of NOACs is common in community practice (almost 1 in 8 patients) and is associated with an increased risk of adverse clinical events.
A significant minority (almost 1 in 8) of U.S. patients in the community received NOAC doses inconsistent with labeling. NOAC over- and underdosing are associated with increased risk for adverse events. (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II ORBIT-AF II; NCT01701817).
Building similarity graph...
Analyzing shared references across papers
Loading...
Steinberg et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69d56dc675589c71d767d084 — DOI: https://doi.org/10.1016/j.jacc.2016.09.966
Benjamin A. Steinberg
Peter Shrader
Laine Thomas
Journal of the American College of Cardiology
Harvard University
Stanford University
Columbia University
Building similarity graph...
Analyzing shared references across papers
Loading...